Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 4/20 | 0.47 |
| ▸ | CASP3 | P42574 | 16/20 | 0.47 |
| ▸ | CASP6 | P55212 | 14/20 | 0.47 |
| ▸ | CASP8 | Q14790 | 14/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13638261 | 1.00 | CASP1 (0.47) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL13638173 | 1.00 | CASP1 (0.47) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL8320800 | 0.90 | CASP1 (0.39) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL12046989 | 0.90 | CASP1 (0.39) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL78289 | 0.90 | CASP3 (0.57) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL78288 | 0.90 | CASP3 (0.57) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL78290 | 0.90 | CASP3 (0.57) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL13793050 | 0.90 | CASP3 (0.57) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL8322179 | 0.90 | CASP3 (0.40) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL3574567 | 0.89 | CASP3 (0.40) | CASP1CASP3CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071618-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071618-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-06 | — | — | US | disclosed |
| US-20100137359-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137359-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-03 | — | — | US | disclosed |
| US-7612091-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612091-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-03 | — | — | US | disclosed |
| WO-2004058718-A1 | 4-OXO-3-(1-OXO-1H-ISOQUINOLIN-2-YLACETYLAMINO)-PENTANOIC ACID ESTER AND AMIDE DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137359-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP3, CASP1, CASP5 | CASP1 2/4885CASP3 1/4885CASP6 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.